Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to relieve menopausal hot flashes.

About VEOZAH (fezolinetant)VEOZAH (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist approved in the U.S. for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

People in the Veozah group had fewer sleep issues vs. those on a placebo at weeks 4 and 12. Improvements in sleep were sustained throughout the study. Improvement in quality of life .

An experimental once-a-day pill that works without hormones significantly reduced the number of hot flashes experienced by women going through menopause and improved their sleep compared to a ...

Today, Astellas Pharma Canada, Inc. is proud to announce the Health Canada approval of VEOZAH® (fezolinetant film-coated tablets), the first and only non-hormonal treatment indicated for the ...

The Food and Drug Administration (FDA) has updated the prescribing information for Veozah (fezolinetant) to include a warning regarding the risk of serious liver injury.. Approved in May 2023 ...

The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to relieve menopausal hot flashes.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor symptoms (VMS ...